Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

New clinical guidelines significantly reduce opioid prescriptions after ear surgery

28

Apr 2026

New clinical guidelines significantly reduce opioid prescriptions after ear surgery

A new retrospective study published in OTO Open, the open-access journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF), demonstrates that the Clinical Practice Guideline (CPG) Opioid Prescribing for Analgesia After Common Otolaryngology Operations has had a measurable and sustained impact on prescribing practices following parotidectomy, which a surgical procedure to remove the parotid gland.

VCU study identifies key factors driving risk of second cancers

28

Apr 2026

VCU study identifies key factors driving risk of second cancers

Risk of developing a subsequent primary cancer varied significantly by age at initial diagnosis, sex, and type of first cancer, according to a study by Oxana Palesh and Susan Hong and colleagues at Virginia Commonwealth University, U.S., published April 28th in the open-access journal PLOS Medicine.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.